Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder

Journal of Clinical Psychopharmacology

Volumn 16, Issue 4, 1996, Pages 324-328

  Ackerman, Deborah L ^a,b   Greenland, Sander ^b   Bystritsky, Alexander ^a   Katz, Richard J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HEART PALPITATION; HUMAN; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; NERVOUSNESS; OBSESSION; PRIORITY JOURNAL; TINNITUS; TREMOR; VERTIGO; XEROSTOMIA;

ADULT; CLOMIPRAMINE; CONSTIPATION; DIZZINESS; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREMOR;

EID: 0030035189     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199608000-00009     Document Type: Article

References (32)

1. Horwitz WA. Physiologic responses as prognostic guides in the use of antidepressant drugs. Am J Psychiatry 1968;125:60-8.
2. Escobar JI, Gomez O, Tuason VB. Depressive subtypes, blood pressure changes and response to treatment. Dis Nerv Syst 1977; 38:76-9.
3. Jarvik LF, Read SL, Mintz J, Neshkes RE. Pretreatment orthostatic hypotension in geriatric depression: predictor of response to imipramine and doxepin. J Clin Psychopharmacol 1983;3:368-72.
4. Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H. Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent. Drug Intell Clin Pharm 1987;21:877-9.
5. Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990;51: 119-23.
6. Stern RS, Marks IM, Wright J, Luscombe DK. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis. Postgrad Med J 1980;56[suppl 1]:134-9.
7. Stern RS, Marks IM, Mawson D, Luscombe DK. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Br J Psychiatry 1988;136:161-6.
8. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8.
9. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. Predictors of treatment response in obsessive compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247-54.
10. Ackerman DL, Greenland S, Bystritsky. A receiver-operator characteristic (ROC) analysis of response to Clomipramine therapy. Psychopharmacol Bull 1996, in press.
11. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
12. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:1012-6.
13. Statistics and Epidemiology Research Corporation. EGRET manual. Seattle, WA, 1992.
14. Rothman K. Modern epidemiology. Boston: Little, Brown and Company, 1986:216.
15. Kellner R. Somatization: theories and research. J Nerv Ment Dis 1990;178:150-60.
16. Ford CV. The somaticizing disorders. Psychosomatics 1986;27: 327-37.
17. Balant-Gorgia AE, Gex-Fabrey M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991;20:447-62.
18. Luscombe DK, Wright J, Stern RS, Mawson D, Marks IM. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis. Postgrad Med J 1980;56[suppl 1]:140-3.
19. McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder, panic disorder. Drugs 1990;39:136-53.
20. Balant-Gorgia AE, Balant LP, Gamme G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report using drug monitoring data. Ther Drug Monit 1989; 11:415-20.
21. Della Corte L, Broadhurts AD, Sgaragli GP, Filippini S, Heeley AF, et al. Clinical response and tricyclic plasma levels during treatment with clomipramine. Br J Psychiatry 1979;134:390-400.
22. Traskman L, Asberg M, Bertilsson L, Cronholm B, Mellstrom B, et al. Plasma levels of clomipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol 1979;26: 600-10.
23. Kasvikis Y, Marks I. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects. Psychopharmacology 1988;95:113-8.
24. Flament HF, Rapoport JL, Berg CJ, Sceery W, Kilts C, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1985;42:977-83.
25. Montgomery SA, McAuley R, Montgomery DB, Dawling S, Braithwaite RA. Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. Postgrad Med J 1980;56[suppl 1]:130-3.
26. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980;37: 1289-94.
27. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174-88.
28. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45:167-72.
29. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear K, Goodman W, Genduso LA. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Paychiatry 1994;51:559-67.
30. Greist J, Chouinad G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
31. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148: 705-13.
32. Insel TR, Foy BF, Cohen RM, Murphy DL Possible development of the serotonin syndrome in man. Am J Psychiatry 1982;139:954-5.